Flagship Inks Another Big Pharma Development Deal, This Time With GSK
Third Big Pharma Deal Since 2022
The deal includes up to 10 medicines, with an initial focus on immunology and respiratory diseases, and is similar to one the VC firm made with Pfizer last year.
